ILLUMINATE-301 continues on track for data later this month
EXTON, Pa., March 1, 2021 (GLOBE NEWSWIRE) – Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today released its financial and operating results for the fourth quarter and fiscal year ended December 31, 2020.
“Tilsotolimod is the most advanced TLR-9 agonist therapy in development, and we look forward to the objective response rate and other important factors. data of ILLUMINATE-301, our pivotal registration trial in advanced refractory anti-PD-1 melanoma, later this month, ”said Vincent Milano, CEO of Idera. “I am very proud of the resilience and tenacity of our team working diligently to achieve this goal, as well as the work underway in ILLUMINATE-206, our micro-satellite stable colorectal cancer trial. In addition, we are in a healthy financial position and expect our current cash flow to fund our operations until the second quarter of 2022, with the potential for additional capital from our operations. security purchase agreements to extend our track until the second quarter of 2023. These resources will help us advance tilsotolimod for patients in need. “
Corporate Update As of September 30, 2020, the following corporate updates have been announced:
The company closed a second tranche under its April 7, 2020 securities purchase agreement for additional aggregate gross proceeds of $ 5.0 million. With this tranche, the Company received $ 25.2 million …
News Highlights Finance
- Headline: Idera Pharmaceuticals Reports Fourth Quarter and Fiscal 2020 Financial Results and Company Update
- Check all news and articles from the Finance news updates.